RedHill and U.S. Army Announce Opaganib's
Ebola Virus Disease
Survival Benefit in U.S. Army-Funded In-Vivo Study

2023-10-03
临床结果临床2期临床3期孤儿药放射疗法
- Novel, oral opaganib, delivered a statistically significant increase in survival time (at 150 mg/kg BID) in a U.S. Army-funded in vivo Ebola virus study
- Opaganib is believed to be the first host-directed molecule to show activity in
Ebola virus disease
, having previously shown in vitro benefit in several strains of
Ebola virus disease
models
- Twice daily administered opaganib has previously demonstrated antiviral benefit in late-stage clinical studies of patients hospitalized with moderate to severe
COVID-19
; opaganib was also selected by the NIH Radiation and Nuclear Countermeasures Program (RNCP) for
Acute Radiation Syndrome
development
TEL AVIV, Israel and RALEIGH, NC, Oct. 3, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that novel, twice daily, oral opaganib[1], delivered a statistically significant increase in survival time when given at 150 mg/kg twice a day (BID) in a United States Army Medical Research Institute of
Infectious Diseases
(USAMRIID) in vivo Ebola virus study, making it the first host-directed molecule to show activity in
Ebola virus disease
.
Rekha Panchal, Ph. D of USAMRIID, who led the study, said: "These results represent an alternative strategy of using a host-directed therapeutic with activity in
Ebola virus disease
in-vivo. Given the unmet medical need and the untapped potential of host-directed antivirals, these results with opaganib, an easy to distribute and administer oral small molecule drug, support its further investigation for use in treating
Ebola
."
The U.S. Army study tested three doses of opaganib (50, 100 and 150 mg/kg BID), against an inactive vehicle control arm. The in vivo study results showed a statistically significant survival increase in mean (SE) survival time of 11.2 (2.6) days in the 150 mg/kg opaganib group (p=0.0279) compared to a mean (SE) survival time of 5.5 (0.4) days in the inactive vehicle control group. A 30% mice survival was observed in the 150 mg/kg treated group compared to the vehicle control.
"We believe opaganib is the most advanced
sphingosine kinase-2 (SPHK2)
selective inhibitor in clinical development, and the more we learn about this molecule, its novel host-directed mechanism of action, and its growing safety and tolerability database, the more promising it appears,"
said Reza Fathi, PhD, RedHill's SVP R&D. "Opaganib has shown its host-directed antiviral potential in clinical and non-clinical studies, warranting further investigation in
Ebola
and other
infectious viral diseases
. Working through the inhibition of multiple pathways, anti-inflammatory properties, the induction of autophagy and apoptosis, and disruption of viral replication and potential inhibition of cell entry via simultaneous inhibition of three sphingolipid-metabolizing enzymes in human cells (
SPHK2
,
DES1
and GCS), we believe opaganib offers a potential breakthrough for fighting a virus capable of causing devastating outbreaks of disease in the countries least equipped to cope with them."
Twice daily administered opaganib has previously demonstrated antiviral benefit in late-stage clinical studies of patients hospitalized with moderate to severe
COVID-19
and was selected by the NIH Radiation and Nuclear Countermeasures Program (RNCP) for
Acute Radiation Syndrome
development.
About
Ebola virus disease
:
According to the Centers for Disease Control and Prevention (CDC),
Ebola disease
is a rare and often deadly illness, caused by
infection
by one of a group of four viruses, known as ebolaviruses, that are found primarily in sub-Saharan Africa and are known as: Zaire, Sudan, Taï Forest (formerly Côte d'Ivoire) and Bundibugyo. Transmission of the disease is mostly through contact with an infected animal (bat or nonhuman primate) or a sick or dead person infected with an ebolavirus. The course of the illness typically progresses from "dry" symptoms initially (such as
fever
,
aches
and
pains
, and
fatigue
), and then progresses to "wet" symptoms (such as
diarrhea
,
vomiting
and unexplained hemorrhaging,
bleeding
or
bruising
) as the person becomes sicker. There are currently only two FDA-approved therapies to treat EVD caused by the Ebola virus, species Zaire ebolavirus, in adults and children; Inmazeb™, a combination of three monoclonal antibodies and Ebanga™, a single monoclonal antibody. Both are intravenously infused direct acting monoclonal antibody antivirals that bind to glycoproteins on the Ebola virus's surface to prevent the virus from entering a person's cells. There is an urgent need for host-directed small molecule therapies that may be effective against multiple strains of ebolavirus, less likely to be impacted by viral mutation, and that are easy to store, distribute and administer, especially in areas where healthcare services and infrastructures may be sub-optimal.
About Opaganib (ABC294640)
Opaganib, a proprietary investigational host-directed and potentially broad-acting drug, is a first-in-class, orally administered
sphingosine kinase-2 (SPHK2)
selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple potential diseases, including
gastrointestinal acute radiation syndrome (GI-ARS)
,
COVID-19
, other viruses as part of pandemic preparedness, and
cholangiocarcinoma
(
bile duct cancer
).
Opaganib's host-directed action is thought to work through the inhibition of multiple pathways, the induction of autophagy and apoptosis, and disruption of viral replication, through simultaneous inhibition of three sphingolipid-metabolizing enzymes in human cells (
SPHK2
, DES1 and GCS).
Opaganib was recently selected by the U.S. Government's Radiation and Nuclear Countermeasures Program (RNCP), led by the National Institute of Allergy and Infectious Diseases
Infectious Diseases
, part of the National Institutes of Health, for the nuclear medical countermeasures product development pipeline as a potential treatment for
Acute Radiation Syndrome (ARS)
. As part of this collaboration, contractors directed and supported by the RNCP will undertake studies, designed in collaboration with RedHill, to test opaganib in established ARS models. In an ARS setting, opaganib is thought to exert its protective effects via an anti-inflammatory mechanism of action involving ceramide elevation and reduction of sphingosine 1-phosphate (S1P) in human cells - suppressing inflammatory damage to normal tissue and thus suppressing toxicity from unintended ionizing radiation exposure. It has also been reported in the literature that inhibition of
sphingosine kinase 2
promotes the viability and robustness of hematopoietic stem cells, even in the face of radiation damage, supporting increased survival.
Opaganib has received Orphan Drug designation from the FDA for the treatment of
cholangiocarcinoma
and has undergone studies in
advanced cholangiocarcinoma
(Phase 2a) and
prostate cancer
. Opaganib also has a Phase 1 chemoradiotherapy study protocol ready for FDA-IND submission.
Opaganib has demonstrated antiviral activity against SARS-CoV-2, multiple variants, and several other viruses, such as
Influenza
A. Being host-targeted, and based on data accumulated to date, opaganib is expected to maintain effect against emerging viral variants. In prespecified analyses of Phase 2/3 clinical data in hospitalized patients with moderate to severe
COVID-19
, oral opaganib demonstrated improved viral RNA clearance, faster time to recovery and significant mortality reduction in key patient subpopulations versus placebo on top of standard of care. Data from the opaganib global Phase 2/3 study has been submitted for peer review and recently published in medRxiv.
Opaganib has also shown positive preclinical results in
renal fibrosis
, and has the potential to target multiple oncology, radioprotection, viral, inflammatory, and gastrointestinal indications.
About USAMRIID
Since 1969, USAMRIID has served as the Department of Defense's (DoD) lead laboratory for medical biological defense research. The core mission is to protect the warfighter from biological threats, while also investigating disease outbreaks and threats to public health. Research conducted at USAMRIID leads to medical solutions—therapeutics, vaccines, diagnostics, and information—that benefit both military personnel and civilians. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Development Command.
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on
gastrointestinal and infectious diseases
. RedHill promotes the gastrointestinal drugs
Talicia®, for the treatment of
Helicobacter pylori (H. pylori) infection
in adults[2], and
Aemcolo®, for the treatment of
travelers' diarrhea
in adults[3]. RedHill's key clinical late-stage development programs include: (i)
opaganib (ABC294640), a first
-in
-class oral broad-acting, host-directed
SPHK2 selective
inhibitor with potential for pandemic preparedness, targeting multiple indications with a U.S. Government collaboration for development for
Acute Radiation Syndrome (ARS)
, a Phase 2/3 program for hospitalized
COVID-19
, and a Phase 2 program in
oncology
; (ii)
upamostat), an oral broad-acting, host-directed, serine protease inhibitor
serine protease
inhibitor with potential for pandemic preparedness is in late-stage development as a treatment for non-hospitalized symptomatic
COVID-19
, and is also targeting multiple other
cancer
and
inflammatory gastrointestinal diseases
; (iii)
RHB-102, with potential UK submission for chemotherapy and radiotherapy induced
nausea
and
vomiting
, positive results from a Phase 3 study for
acute gastroenteritis
and
gastritis
and positive results from a Phase 2 study for
IBS-D
; (iv)
RHB-104, with positive results from a first Phase 3 study for
Crohn's disease
; and (v)
RHB-204, a Phase 3-stage program for
pulmonary nontuberculous mycobacteria (NTM) disease
.
More information about the Company is available at: www.redhillbio.com / twitter.com/RedHillBio.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, statements regarding the intended use of net proceeds therefrom, may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include statements regarding anticipated the addition of new revenue generating products, out-licensing of the Company's development pipeline assets, timing of opaganib's development for Acute Radiation Syndrome, non-dilutive development funding from RHB-107 and its inclusion in a key platform study. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, market and other conditions, the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication, the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-study requirements will not be met and/or that the Phase 3 study of RHB-107 in COVID-19 outpatients will not be approved to commence or if approved, will not be completed or, should that be the case, that we will not be successful in obtaining alternative non-dilutive development funding for RHB-107, the risk that HB-107's late-stage development for non-hospitalized COVID-19 will not benefit from the resources redirected from the terminated RHB-204 Phase 3 study, that the Phase 2/3 COVID-19 study for RHB-107 may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional COVID-19 studies for opaganib and RHB-107 are likely to be required, as well as risks and uncertainties associated with the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia®; (v) the Company's ability to successfully commercialize and promote Talicia® and Aemcolo®; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 28, 2023. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.
1. Opaganib is an investigational new drug, not available for commercial distribution.
2. Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of
H. pylori infection
in adults. For full prescribing information see: www.Talicia.com.
3. Aemcolo® (rifamycin) is indicated for the treatment of
travelers' diarrhea
caused by noninvasive strains of Escherichia coli in adults. For full prescribing information see: www.aemcolo.com.
Category: R&D
Logo - https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg
Company contact:
Adi Frish
Chief Corporate & Business Development Officer
+972-54-6543-112
[email protected]
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
埃博拉病毒性疾病,新型冠状病毒感染,急性放射综合征
[+26]
靶点
SPHK2,DES1,Serine protease
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。